A case of refractory thrombotic thrombocytopenic purpura treated with plasmapheresis and rituximab

A case of refractory thrombotic thrombocytopenic purpura treated with plasmapheresis and rituximab

Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening disorder with no prevalence or incidence studies in sub-Saharan Africa. Acquired TTP has several causes, all of which lead to decreased activity of von Willebrand factor cleaving protease (ADAMTS13) due to autoantibodies that are...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:SAMJ: South African Medical Journal 2016-07, Vol.106 (7), p.689-691
Hauptverfasser: Kirui, N., Sokwala, A.
Format: Artikel
Sprache:eng
Schlagworte:
Africa South of the Sahara
Diagnosis
Drug therapy
Health Care Sciences & Services
Health Policy & Services
Humans
Immunologic Factors - therapeutic use
Male
Medical Ethics
Medicine, General & Internal
Medicine, Legal
Medicine, Research & Experimental
Methods
Middle Aged
Patient outcomes
Plasmapheresis
Purpura, Thrombotic Thrombocytopenic - diagnosis
Purpura, Thrombotic Thrombocytopenic - therapy
Rituximab - therapeutic use
Thrombocytopenic purpura
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening disorder with no prevalence or incidence studies in sub-Saharan Africa. Acquired TTP has several causes, all of which lead to decreased activity of von Willebrand factor cleaving protease (ADAMTS13) due to autoantibodies that are directed towards ADAMTS13. We report a case of a 46-year-old man who presented with most of the classic clinical manifestations of TTP.
ISSN:0256-9574
2078-5135
2078-5135
DOI:10.7196/SAMJ.2016.v106i7.9856